Scope and Claiming Analysis for US Patent 7,858,609 (Ganaxolone Solid Stabilized Particles)

US 7,858,609 claims a specific composition and performance-controlled particle system for oral ganaxolone: solid stabilized particles with defined size (D50 50 to 500 nm) produced by using (i) a hydrophilic polymer, (ii) a wetting agent, and (iii) a low-molecular-weight organic “complexing agent” (MW < 550) bearing a phenol or aromatic ester or aromatic acid moiety, in tight w/w ranges. Claim scope then cascades into formulation excipient embodiments, harsh-medium dispersion performance (SGF/SIF at 36–38°C), and downstream oral dosage constructs with pharmacokinetic performance language (fed/fasted AUC and Cmax ratios and absolute ranges). Multiple dependent claims further lock: specific complexing agents (parabens, benzoic acid/salts, methyl anthranilate), polymer selections (HPMC and PVA and PVP/VA), wetting agents (SLS and docusate salts), and additional excipient classes (ionic dispersion modulators, water-soluble spacers, disintegrants, surfactants, plasticizers, etc.).

What does US Patent 7,858,609 claim about ganaxolone particle stabilization?

Core independent claim (Claim 1) is composition-of-matter plus a functional stabilization endpoint tied to size control. The invention is “solid stabilized particles” comprising:

Active: ganaxolone
Matrix/structure: hydrophilic polymer
Surface wetting: wetting agent
Stabilization mechanism input: complexing agent with:
- MW < 550
- small organic molecule
- includes moiety selected from:
  - phenol moiety
  - aromatic ester moiety
  - aromatic acid moiety
- amount: 0.05% to 5% w/w (based on particle solids)
Particle size:
- volume weighted median diameter (D50): ~50 to 500 nm

Functional language embedded in Claim 1 Claim 1 does not only recite components. It states the complexing agent “stabilizes particle growth after an initial particle growth and endpoint is reached.” That is a process-performance coupling that can be used in enforcement even where a challenger disputes why size remains controlled after the initial growth phase.

Key freedom retained by Claim 1

Hydrophilic polymer is not limited in Claim 1 (dependent claims do the narrowing).
Wetting agent not limited in Claim 1 (dependent claims narrow).
Complexing agent is broad by structural category and MW cap, but then narrowed in dependent claims to particular agents.
Particle size is a quantitative hard stop: D50 50–500 nm.

Scope-critical numerical claim anchors

Complexing agent: 0.05–5% w/w
D50: 50–500 nm
Later claims impose performance criteria in SGF/SIF and additional PK parameters.

How broad are the complexing agent claims in US 7,858,609?

Claim 1 complexing agent scope is broad structurally, then narrows by dependent claims.

What moieties qualify under Claim 1?

A “small organic molecule” (MW < 550) having one of the following moieties:

phenol moiety
aromatic ester moiety
aromatic acid moiety

What are the explicit dependent selections?

Claim 12: complexing agent selected from:
- parabens
- benzoic acid
- pharmaceutically acceptable salts and mixtures
Claim 13: parabens limited to:
- methylparaben, ethylparaben, propylparaben (and salts/mixtures)
Claim 57: complexing agent comprises benzoic acid or salts
Claim 58: complexing agent comprises methyl anthranilate
Claim 59 and Claim 60: methyl paraben and propyl paraben (with mixtures) explicitly in the 0.05–5% band

Commercial implication This claim structure gives the patent estate leverage against competitors that use common preservative-type aromatic esters/acids (parabens) and related aromatic-acid/phenolic chemistries, at least where the resulting particle system still achieves the D50 and SGF/SIF size-growth limits.

Dose-formulation-independent vs dependent complexity

Claim 1 covers the particles regardless of dosage form. Claims 9–11 and onward then add powder and tablet/capsule incorporation. This matters for generic challengers: even if they change dosage architecture, Claim 1 still targets the particulate composition.

What are the hydrophilic polymer and wetting agent constraints?

Hydrophilic polymer

Claim 1 requires a hydrophilic polymer but gives no identity.
Claim 2: polymer amount 3–50% w/w
Claim 14: polymer selected from:
- cellulosic polymers
- vinyl polymers
Claim 15: cellulose ether
Claim 16: hydroxypropylmethylcellulose (HPMC)
Claim 17: polyvinyl alcohol (PVA)
Claim 18: vinyl pyrrolidone/vinyl acetate copolymer (S630)

Wetting agent

Claim 3: wetting agent amount 0.01–10% w/w
Claim 19: wetting agent selected from:
- sodium lauryl sulfate (SLS)
- docusate salt
- mixtures

Moisture/surfactant adjacency risks for would-be entrants

A generic or formulation designer seeking to “invent around” by changing surfactants would need to ensure:

D50 still 50–500 nm, and
the SGF/SIF size growth rules still hold,
and, if litigating, whether their polymer and wetting agent still fall within these dependent limitations.

What is the claimed particle size profile (D50) and how tight is it?

The estate uses D50 both as:

a baseline particle definition, and
a stability/performance test metric in SGF/SIF.

Baseline particle size

Claim 1: D50 50–500 nm
Claim 11: D50 in distilled water 100–350 nm

SGF/SIF dispersion size stability constraints

Multiple claims require that, under harsh media and heat:

Increase in D50 ≤ 150%
and SGF/SIF D50 < 750 nm under defined conditions.

Representative claims:

Claim 4: SGF or SIF at 0.5–1 mg/mL, 36–38°C, 1 hour
Claim 5: explicit 15 mL volume, 0.5–1 mg/mL, heated 1 hour
Claim 8: repeats the core stability test for dependent polymer amount embodiments

Table: size and stability numerical thresholds in key dependent claims

Claim	Medium	Concentration	Temp/Time	D50 growth rule	Upper bound on D50 in SGF/SIF
4	SGF or SIF	0.5–1 mg/mL	36–38°C, 1 hr	increase ≤ 150%	< 750 nm
5	SGF or SIF (15 mL)	0.5–1 mg/mL	36–38°C, 1 hr	increase ≤ 150%	< 750 nm
8	SGF or SIF	0.5–1 mg/mL	36–38°C, 1 hr	increase ≤ 150%	< 750 nm
37	SGF/SIF	0.5 mg/mL	36–38°C, 1 hr, no stirring	increase ≤ 150%	< 750 nm
38	SGF/SIF	0.5–1 mg/mL	36–38°C, 1 hr, Type II + 75 RPM	increase ≤ 150%	< 750 nm
47	SGF/SIF	0.5–1 mg/mL	36–38°C, 1 hr, Type II + 75 RPM	increase ≤ 150%	< 750 nm
49	sequential SGF then SIF	0.5–1 mg/mL	36–38°C, 1 hr SGF + 3 hr SIF	increase not stated as ≤150% but D50 remains < 750 nm	< 750 nm

Enforcement angle These are tight, testable parameters. If an accused product’s D50 in SGF/SIF exceeds the cap or the growth multiplier, it creates a binary factual dispute suitable for expert evidence.

What formulations are protected: powders, immediate release, and controlled release?

Powder embodiment

Claim 9: the particles are “in the form of a powder.” This is relevant for parties shipping intermediate stabilized particle material or for dry-mix approaches.

Tablet/capsule embodiment

Claim 10: particles incorporated into a dosage form selected from:
- tablet or capsule

Immediate release vs controlled release

Claim 46: solid dosage form is immediate release
Claim 48: solid dosage form is controlled release

Controlled release further ties to extended media exposure:

Claim 49: D50 < 750 nm after SGF for 1 hour followed by SIF for 3 additional hours under Type II + 75 RPM.

Hybrid delivery (immediate + controlled release components)

Claim 50: oral solid dosage form has:
- controlled release component with first portion of particles
- immediate release component with second portion
- both portions maintain D50 50–500 nm
Claim 51: ganaxolone ratio controlled release to immediate release 4:1 to 1:4
Claims 52–53: therapeutic effect 8–24 hours after administration for controlled release and hybrid formats.

What excipients are included in the protected embodiments?

Claims 20–36 define a broad excipient “further comprising” structure, but dependent claims narrow classes.

Base dosage form with excipients

Claim 20: solid dosage form comprising stabilized particles plus at least one pharmaceutically acceptable excipient

Excipients enumerated in Claim 21

At least one selected from:

ionic dispersion modulator
water soluble spacer
disintegrant
binder
surfactant
plasticizer
lubricant
combinations/mixtures

Ionic dispersion modulator

Claim 22: excipient comprises ionic dispersion modulator
Claim 23: amount 1–50% w/w
Claims 24–27: ionic dispersion modulator is a salt, including inorganic salt with specific metal cations
- sodium chloride specifically in Claim 27
Claims 28–29: organic salt options include citrate, succinate, fumarate, malate, maleate, tartrate, glutarate, lactate

Water soluble spacer

Claim 30: excipient comprises water soluble spacer
Claim 31: amount 2–60% w/w
Claim 32: water soluble spacer is saccharide or ammonium salt
Claim 33: saccharide examples
- fructose, sucrose, glucose, lactose, mannitol

Other specific excipient-dependent claims

Claim 34: disintegrant examples
- cross-linked sodium carboxymethylcellulose
- crospovidone
Claim 35: surfactant is polysorbate
Claim 36: plasticizer is polyethylene glycol

Design-around reality A challenge that only swaps excipients may still face infringement under Claim 1, if their particle composition hits the D50 and complexing agent/polymers/wetting agent features. Excipient changes mainly affect dependent claims 20–49 rather than Claim 1’s particle definition.

What pharmacokinetic performance is claimed in US 7,858,609?

Claims 39–45 add product-performance language tied to fed vs fasted plasma exposure after oral administration in adult subjects. These create a second infringement path if the accused product is tested and shows the specified exposure ratios and ranges.

Fed vs fasted AUC and Cmax ratios

Claim 39: AUC(0–τ) fed/fasted 1:1 to 4:1
Claim 40: Cmax fed/fasted 1.5:1 to 7:1

Absolute PK ranges and steady state

Claim 41: D50 50–1000 nm (note: broader than Claim 1) and AUC(0–24) fasted *100–375 ngh/mL for 200–500 mg** oral dose
Claim 42: fasted Cmax 25–70 ng/mL (200–500 mg dose)
Claim 43: fed AUC(0–48) *400–1200 ngh/mL**
Claim 44: fed Cmax 60–250 ng/mL
Claim 45: steady state Cmax/Cmin ≤ 4:1 (fed or fasted), dose 200–500 mg

PK claim positioning

These PK claims are dependent on earlier dosage/excipient and particle provisions (Claim 39 depends on Claim 38/20 chain). Practically, they are strongest if an accused product matches the earlier formulation elements (particles plus dosage form parameters).

Does US 7,858,609 contain potential overlapping or inconsistent claim breadth?

Yes, in the estate itself: Claim 41 allows D50 50–1000 nm for PK-focused language, while Claim 1 limits D50 to 50–500 nm. In litigation, this can matter for scope mapping:

A formulation could be argued to fall within Claim 41’s D50 range even if it exceeds 500 nm, if other dependencies are satisfied and the specific claim construction permits the broader dependent range to control.

Also, Claims 37 and 47 introduce processing distinctions:

Claim 37: “without stirring”
Claim 38 and 47: Type II apparatus with 75 RPM

Those are likely to be used to distinguish test results.

What does this imply for the ganaxolone patent landscape and generic entry risks?

Even without the rest of the US patent family metadata, the claim architecture indicates where competitors will be exposed:

High-risk infringement vectors

Using parabens (methyl/ethyl/propyl) or benzoic acid salts or methyl anthranilate at 0.05–5% w/w with:
- a hydrophilic polymer in 3–50%
- wetting agent 0.01–10%
- D50 50–500 nm
Achieving the required SGF/SIF performance:
- SGF/SIF D50 < 750 nm
- D50 growth ≤ 150% under specified concentration/temperature/time or Type II settings.
Building dosage forms (tablet/capsule; immediate and/or controlled release) that retain those particle properties and match any claimed PK performance windows.

Medium-risk vectors

Changing dosage form (IR/CR/hybrid) without changing particles likely still risks Claim 1.
Changing excipients may avoid some dependent claims but not Claim 1.

Lower-risk vectors (not guaranteed)

Complexing agents outside the MW < 550 + phenol/aromatic ester/aromatic acid moiety set.
Wetting agents not in the dependent lists (SLS/docusate), if they also alter dispersion to fail SGF/SIF size-growth criteria.

What jurisdictions, Orange Book status, or related litigation ties can be inferred from the provided text?

No jurisdictional, Orange Book, or litigation status can be established from the claim text alone. The prompt provides only the claim list. Without bibliographic record evidence (filing/priority dates, assignee, publication number, prosecution history) and without Orange Book listing identifiers or case dockets, no definitive landscape statement can be made.

Key Takeaways

US 7,858,609 is centered on ganaxolone solid stabilized particles with D50 50–500 nm using a hydrophilic polymer, wetting agent, and MW < 550 aromatic-acid/ester/phenol complexing agent at 0.05–5% w/w.
The patent adds testable SGF/SIF dispersion stability: SGF/SIF D50 < 750 nm and D50 growth ≤ 150% under specified concentration and temperature/time, with further distinctions based on stirring/apparatus settings.
Dependent claims narrow to concrete chemicals: HPMC/PVA/S630 for polymers; SLS/docusate for wetting agents; parabens and benzoic acid and methyl anthranilate for complexing agents.
The estate expands into tablet/capsule embodiments with detailed excipient class constraints (ionic dispersion modulators, water-soluble spacers, disintegrants, surfactants, plasticizers).
The patent also includes fed vs fasted pharmacokinetic performance windows (AUC and Cmax ratios and absolute ranges) and steady-state Cmax/Cmin constraints, creating additional factual infringement hooks tied to oral dosing.

FAQs

1) Which parts of US 7,858,609 are most likely to be litigated first?
Claim 1’s composition requirements (polymer + wetting agent + aromatic-acid/ester/phenol complexing agent at MW < 550 and 0.05–5% w/w) and the SGF/SIF D50 stability limits in Claims 4/5/8/37/38/47/49 are the most testable and easiest to map to accused products.

2) Do tablet and capsule embodiments expand risk beyond the particle claims?
They mainly add dependent coverage. Claim 1 already covers particles. Tablet/capsule claims (Claims 10, 37–50) matter when the accused product’s infringement is argued through dosage-form-specific tests (e.g., SGF/SIF performance of the dosage form).

3) Can switching from parabens to another complexing agent avoid the patent?
Avoidance depends on whether the alternative still fits Claim 1’s complexing agent criteria (MW < 550 and phenol/aromatic ester/aromatic acid moiety) and whether the resulting formulation still satisfies the D50 and SGF/SIF stability constraints.

4) What SGF/SIF conditions are specifically pinned down?
Concentration 0.5–1 mg/mL, 36–38°C, 1 hour (and in Claim 5, 15 mL), with apparatus/stirring specified in certain claims (Type II, 75 RPM, and one claim with “without stirring”). Claim 49 extends SGF then SIF for 1 hour + 3 hours.

5) How do the PK claims change the evidentiary burden in enforcement?
PK claims (Claims 39–45) require plasma exposure measurement after dosing in fed or fasted states, plus mapping to the specific ratio and absolute AUC/Cmax ranges and the dosing band (200–500 mg). They can become decisive if the formulation matches the earlier dependent claim elements and PK testing supports the windows.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	7,858,609	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1959966	⤷ Start Trial	122024000005	Germany	⤷ Start Trial
European Patent Office	1959966	⤷ Start Trial	C202430002	Spain	⤷ Start Trial
African Regional IP Organization (ARIPO)	3071	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,858,609